Eighteen IPOs raised a combined $5.3 billion in April, above the 10-year historical average by deal count and proceeds (16 IPOs, $3.7B). It was the busiest month for both overall new issuance and $100+ million IPOs since November 2021. Nine deals raised $100...read more
Three IPOs priced in the first week of April, led by a sizable biotech. The calendar should see more activity coming up, thanks to some large launches and notable new filings. Neuro and inflammation biotech Contineum Therapeutics (CTNM)...read more
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for inflammatory diseases, raised $110 million by offering 6.9 million shares at $16, the low end of the range of $16 to $18. The company offered 1.9 million fewer shares than...read more
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for IPF and multiple sclerosis, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of...read more
Renaissance Capital's April IPO Market Update
Eighteen IPOs raised a combined $5.3 billion in April, above the 10-year historical average by deal count and proceeds (16 IPOs, $3.7B). It was the busiest month for both overall new issuance and $100+ million IPOs since November 2021. Nine deals raised $100...read more
US IPO Weekly Recap: April IPO market gets a boost from large launches and new filings
Three IPOs priced in the first week of April, led by a sizable biotech. The calendar should see more activity coming up, thanks to some large launches and notable new filings. Neuro and inflammation biotech Contineum Therapeutics (CTNM)...read more
Neuro and inflammation biotech Contineum Therapeutics prices downsized IPO at $16, the low end of the range
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for inflammatory diseases, raised $110 million by offering 6.9 million shares at $16, the low end of the range of $16 to $18. The company offered 1.9 million fewer shares than...read more
Neuro and inflammation biotech Contineum Therapeutics sets terms for $150 million IPO
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for IPF and multiple sclerosis, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of...read more